^
    Back
    Association details:
    Biomarker:KRAS mutation + KMT2C mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Onco Targets Ther
    Title:

    Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China

    Published date:
    09/21/2022
    Excerpt:
    Likewise, patients with KRAS and KMT2C co-mutations responded best to immunotherapy, better than those with KRAS mutations alone...
    DOI:
    https://doi.org/10.2147/OTT.S381825